Thioredoxin-1 maintains mechanistic target of rapamycin (mTOR) function during oxidative stress in cardiomyocytes by Oka, Shin-Ichi et al.
Thioredoxin-1 maintains mechanistic target of rapamycin
(mTOR) function during oxidative stress in cardiomyocytes
Received for publication, July 19, 2017, and in revised form, September 6, 2017 Published, Papers in Press, September 22, 2017, DOI 10.1074/jbc.M117.807735
Shin-ichi Oka‡1, Tsuyoshi Hirata‡, Wataru Suzuki‡, Daichi Naito‡, Yanbin Chen§, Adave Chin‡, Hiroaki Yaginuma‡,
Toshiro Saito‡, Narayani Nagarajan‡, Peiyong Zhai‡, Santosh Bhat‡, Kevin Schesing‡, Dan Shao‡,
Yoko Hirabayashi¶, Junji Yodoi, Sebastiano Sciarretta**, and Junichi Sadoshima‡2
From the ‡Department of Cell Biology andMolecular Medicine, Rutgers Biomedical and Health Sciences, Newark, New Jersey
07101, the §Department of Respiratory Medicine, First Affiliated Hospital of SoochowUniversity, 899 Pinghai Road, Suzhou
215000, China, the ¶Division of Cellular andMolecular Toxicology, Center for Biological Safety and Research, National Institute of
Health Sciences, Tokyo 158-8501, Japan, the Department of Biological Responses, Laboratory of Infection and Prevention,
Institute for Virus Research, Kyoto University, Sakyo-ku, Kyoto 606-8397, Japan, and the **Department of Medical-Surgical Science
and Biotechnologies, University of Rome, Latina 04100, Italy
Edited by Ruma Banerjee
Thioredoxin 1 (Trx1) is a 12-kDa oxidoreductase that cata-
lyzes thiol-disulfide exchange reactions to reduce proteins with
disulfide bonds. As such, Trx1 helps protect the heart against
stresses, such as ischemia and pressure overload. Mechanis-
tic target of rapamycin (mTOR) is a serine/threonine kinase
that regulates cell growth, metabolism, and survival. We
have shown previously that mTOR activity is increased in
response to myocardial ischemia–reperfusion injury. How-
ever, whether Trx1 interacts with mTOR to preserve heart
function remains unknown. Using a substrate-trapping mu-
tant of Trx1 (Trx1C35S), we show here that mTOR is a
direct interacting partner of Trx1 in the heart. In response to
H2O2 treatment in cardiomyocytes, mTOR exhibited a high
molecular weight shift in non-reducing SDS-PAGE in a 2-mer-
captoethanol-sensitive manner, suggesting that mTOR is oxi-
dized and forms disulfide bonds with itself or other proteins.
The mTOR oxidation was accompanied by reduced phosphory-
lation of endogenous substrates, such as S6 kinase (S6K) and
4E-binding protein 1 (4E-BP1) in cardiomyocytes. Immune
complex kinase assays disclosed that H2O2 treatment dimin-
ished mTOR kinase activity, indicating that mTOR is inhibited
by oxidation. Of note, Trx1 overexpression attenuated both
H2O2-mediated mTOR oxidation and inhibition, whereas Trx1
knockdown increased mTOR oxidation and inhibition. More-
over, Trx1 normalized H2O2-induced down-regulation of
metabolic genes and stimulation of cell death, and an mTOR
inhibitor abolished Trx1-mediated rescue of gene expression.
H2O2-induced oxidation and inhibition of mTOR were attenu-
ated when Cys-1483 of mTOR was mutated to phenylalanine.
These results suggest that Trx1 protects cardiomyocytes against
stress by reducing mTOR at Cys-1483, thereby preserving the
activity of mTOR and inhibiting cell death.
Reactive oxygen species (ROS),3 such as hydrogen peroxide
(H2O2), are generated by various biological reactions, including
mitochondrial respiration and activation of ROS-producing
enzymes such as NADPH oxidases. Increased ROS are fre-
quently observed under various pathological and stressed con-
ditions and are generally considered to promote the pathology
because of oxidative damage of proteins, lipids, and DNAs. To
protect against ROS, cells express antioxidant systems, includ-
ing thioredoxins and glutathione, and reducing enzymes, such
as superoxide dismutase, and catalase.
Thioredoxin 1 (Trx1) is a reducing enzyme evolutionarily
conserved from prokaryotes to mammals that regulates a
wide range of biological reactions, including DNA synthesis,
immune reaction, transcription, and stress resistance (1). Trx1
possesses two cysteine residues in its catalytic center compris-
ing a CXXC motif, which reduces the disulfides of oxidized
proteins through disulfide formation with the catalytic center.
Oxidized Trx1 is then reduced by Trx reductase. Trx1 protects
against oxidative stress (2). The cytoprotective effect of Trx1
renders resistance to ischemic injury in cardiomyocytes (3, 4)
and drug resistance in cancer cells (5). Although Trx1 itself
does not react effectively with H2O2, Trx1 reduces H2O2
through peroxiredoxins, Trx1-dependent peroxidases (6). In
addition, Trx1 directly reduces specific substrates, including
NFB, class II histone deacetylases, caspase, and AMP-acti-
vated protein kinase (AMPK), through thiol-disulfide exchange
reactions (7). Trx1 is a unique redox regulator that is deeply
involved in signal transduction. Identification and character-
ization of Trx1 substrates may allow discovery of novel biolog-
ical reactions that serve to counteract oxidative stress.
The mechanistic target of rapamycin (mTOR) is an evolu-
tionarily conserved serine/threonine kinase that regulates
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cell growth, survival, metabolism, and protein synthesis (8).
There are two distinct mTOR complexes: mTOR complex 1
(mTORC1) and mTORC2. Although both complexes contain
mTOR as a common kinase subunit, mTORC1 and mTORC2
phosphorylate distinct substrates, thereby regulating distinct
biological reactions. mTOR has been shown to be essential in
cardiac function, with cardiac-specific knockout resulting in
fatal dilated cardiomyopathy (9). On the other hand, either
genetically induced or pharmacological mTOR inhibition pro-
tects the heart in several pathological contexts (10). Several
studies have demonstrated that mTOR is regulated by cellular
redox status. There are conflicting reports showing thatmTOR
is alternatively activated or inhibited by oxidative stress, which
could be cell type- and oxidant-dependent (11–13). We dem-
onstrated previously that mTOR activity is increased in
response to myocardial ischemia–reperfusion injury (14).
However, whether mTOR directly senses cellular redox status
and the potential impact of mTOR redox regulation in cardiac
pathophysiology remain unknown.
Using cardiac-specific Trx1 substrate-trapping mutant
(Trx1C35S) mice, we here identified that mTOR is a Trx1 sub-
strate in the heart (4). In this study, we show that mTOR was
subjected to redoxmodification.mTOR formed intermolecular
disulfides in response to oxidation that were reduced by Trx1.
mTOR oxidation in cardiomyocytes was linked to mTOR inhi-
bition.We propose that the cardioprotective effects of Trx1 are
partly mediated through mTOR.
Results
Identification ofmTOR as a Trx1 substrate in cardiomyocytes
Trx1 possesses two cysteines (Cys-32 and Cys-35) in its cat-
alytic center. During the catalytic reaction, Cys-32 forms a
disulfide bond with a substrate, and then Cys-35 cleaves it.
Thus, a Trx1C35S mutant stably forms a disulfide with sub-
strates (Fig. 1A). To gain insight into how Trx1 facilitates car-
dioprotective effects under ischemic conditions, we screened
potential Trx1 substrates using cardiac-specific transgenic
mice with N-terminal FLAG-tagged and C-terminal HA-
tagged Trx1C35S (FLAG-Trx1C35S-HA) subjected to ische-
mia. Trx1C35S was immunoprecipitated with anti-FLAG
antibody, and the substrates were screened with Western blot
analyses. As shown in Fig. 1B, mTOR was immunoprecipitated
with Trx1C35S under both basal and ischemic conditions.
Interaction between mTOR and FLAG-TrxC35S-HA was also
observed in primary cultured cardiomyocytes, and the interac-
tion was abolished with a lysis buffer containing DTT, a reduc-
ing agent (Fig. 1C), suggesting that the interaction between
Trx1 and mTOR is mediated through an intermolecular disul-
fide bond. The interaction between mTOR and FLAG-
TrxC35S-HA was not significantly enhanced under stress con-
ditions such as ischemia or H2O2 treatment, suggesting that
Trx1 constantly reduces mTOR, with or without oxidative
stress (Fig. 1, B andC). Interaction between Trx1 without C35S
mutation and mTOR was not detected even in the presence of
H2O2 (Fig. 1D), suggesting that the interaction between Trx1
and mTOR is transient.
mTOR forms intermolecular disulfide bonds
To test whether mTOR forms an intermolecular disulfide
bond in response to oxidation,Western blot analyses were per-
formed with SDS-PAGE under non-reducing conditions. In
response to H2O2 treatment, some mTOR in cardiomyocytes
exhibited a band shift to a high molecular weight, which was
abolished in the presence of a loading buffer containing 2-mer-
captoethanol, a reducing agent, suggesting that mTOR forms
intermolecular disulfide bonds (Fig. 1E). To test the possibility
that one mTOR molecule forms a disulfide bond with another
mTOR molecule, FLAG- and Myc-tagged mTOR were co-ex-
pressed in HEK293 cells. We used a lysis buffer with a high salt
content (1 M NaCl) to dissociate any non-covalently bound
mTOR binding proteins. After H2O2 treatment, FLAG-mTOR
was immunoprecipitated with anti-FLAG antibody, and the
immune complex was probed with anti-Myc antibody. As
shown in Fig. 1F, Myc-mTOR was not immunoprecipitated
with FLAG-mTOR from cells without H2O2 treatment, sug-
gesting that the high-salt lysis buffer dissociates Myc-mTOR
from FLAG-mTOR. However, with H2O2 treatment, Myc-
mTOR was detected as both shifted and non-shifted bands,
indicating thatmTORoligomerization through disulfide bond-
ing (as reflected by the shifted band) and non-covalent binding
(as reflected by the non-shifted band) is enhanced by H2O2.
These results suggest three possibilities. First, FLAG-mTOR
forms an intermolecular disulfide bond with Myc-mTOR (Fig.
1G, topmodel). Second, twomolecules ofmTOR form disulfide
bonds with the same other molecule without binding to one
another directly (Fig. 1G, center model). Third, FLAG-mTOR
binds to Myc-mTOR but not through a disulfide bond, and
Myc-mTOR and FLAG-mTOR form an intermolecular disul-
fide bond with another molecule (Fig. 1G, bottom model).
H2O2 inhibits phosphorylation ofmTOR substrates
To examine how mTOR is regulated by oxidation, the effect
ofH2O2uponphosphorylation ofmTORat Ser-2481 (known to
be autophosphorylated (15)) and Ser-2448 (known to correlate
with mTORC1 activity (16)) and upon known mTOR sub-
strates was examined in cardiomyocytes. As shown in Fig. 2, A
and B, H2O2 dose-dependently increased oxidation of mTOR.
There was a trend that phosphorylation of mTOR and
mTORC1 substrates, such as S6K and 4EBP1, was increased in
the presence of H2O2 at concentrations ranging from 10 to 100
M (mTOR and S6K) and from 10 to 300M (4EBP1) at 10min.
However, their phosphorylation was significantly inhibited in
the presence ofH2O2 at concentrations ranging from100 to 500
M (mTOR) and from 300 to 500 M (S6K and 4EBP1) at the
later time point of 30 min. In contrast, phosphorylation of Akt,
a substrate of mTORC2, was slightly increased in the presence
of H2O2 at concentrations ranging from 30 to 500M at 10min
and from 10 to 300 M at 30 min without reaching statistical
significance. H2O2 (100 M) time-dependently induced oxida-
tion ofmTOR, peaking at 60min. Phosphorylation ofmTOR at
Ser-2448 and Ser-2481 and of S6K was inhibited by H2O2 in a
time-dependent manner. H2O2 time-dependently inhibited
phosphorylation of 4EBP1, peaking at 60 min, with a partial
recovery at 120 and/or 240 min (Fig. 2, C andD). Phosphoryla-
Trx1 as a co-factor ofmTOR
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tion of the mTORC2 substrate Akt was increased at 10 min,
normalized at 30 and 60 min, and increased at 120 to 240 min,
although none of the time points showed statistical significance
relative to the basal level. Thus, mTOR oxidation is associated
with reduced phosphorylation of mTORC1 substrates. We
also tested whether the phosphorylation of mTOR sub-
strates induced by activation of mTOR by upstream stimuli
is inhibited by H2O2. To this end, we stimulated mTOR with
insulin. As shown in Fig. 2, E and F, insulin-induced phos-
phorylation of S6K, 4EBP1, and Akt was significantly inhib-
ited in the presence of H2O2. Taken together, these results
suggest that H2O2 inhibits insulin-induced phosphorylation
of mTORC1 and mTORC2 substrates.
Oxidative stress inhibits mTOR kinase activity
To test whether mTOR kinase activity is inhibited by H2O2,
an in vitro kinase assay was performed. mTOR was immuno-
precipitated fromH2O2-treated cardiomyocytes and incubated
with recombinant 4EBP1 and ATP. As shown in Fig. 3, mTOR-
induced phosphorylation of 4EBP1 was inhibited by H2O2.
These results suggest that oxidative stress inhibits mTOR
kinase activity.
Common and specific effects of oxidants inmTOR regulation
In contrast to the H2O2-induced mTOR inhibition in car-
diomyocytes, other oxidants, such as PAO, a thiol-cross-linking
reagent that covalently binds to thiol groups, and diamide, a
Figure 1. The mTOR kinase is a Trx1 substrate. A, schematic of how the Trx1 substrate-trapping mutant (Trx1C35S) works. B, Trx1C35S traps mTOR in the
heart. After 3 h of ischemia, FLAG-Trx1C35S was immunoprecipitated (IP) with anti-FLAG antibody. C, Trx1C35S traps mTOR in cultured cardiomyocytes.
FLAG-Trx1C35S-HA was expressed via an adenovirus vector. Cardiomyocytes were incubated with 100 M H2O2 for 30 min, and then FLAG-Trx1C35S-HA was
immunoprecipitatedwith anti-FLAGantibodywithorwithout 1mMDTT.D, stable interactionbetweenendogenousmTORandTrx1 is not observed in cultured
cardiomyocytes. Cardiomyocytes were treated with 100 M H2O2 for 30 min, and endogenous mTOR was immunoprecipitated. E, mTOR intermolecular
disulfide formation in primary cultured cardiomyocytes. Cardiomyocytes were incubated with 100 M H2O2 for 30 min (left panel) or 500 M H2O2 for 10 min
(right panel). F, mTOR forms disulfide bonds with either mTOR itself or other proteins. FLAG-mTOR andMyc-mTORwere expressed in HEK293 cells. After H2O2
treatment (3mM, 30min), FLAG-mTORwas immunoprecipitatedwith anti-FLAG antibody.G, data interpretation of the results shown in F. E and F, Western blot
analyses were performed after SDS-PAGE under non-reducing (without 2ME) conditions. Ox, oxidized form; Red, reduced form. Western blot results were
verified by two (B–D and F) and three (E) additional independent experiments.
Trx1 as a co-factor ofmTOR
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thiol-oxidizing reagent that induces disulfide bonds, are
reported to activate mTOR signaling in HEK293 cells and
mouse embryonic fibroblasts (11, 12). Whether and how
mTOR is regulated by different oxidants in cardiomyocytes is
an important consideration. To test whether PAO and diamide
induce mTOR disulfide bond formation, mTOR oxidation
(band shift) was examined. Unlike H2O2, PAO did not induce a
band shift ofmTOR, probably because PAO covalently binds to
thiol groups to prevent disulfide bond formation. In contrast,
diamide did induce a band shift, similar to the effect of H2O2
(Fig. 4C). PAO and diamide inhibited phosphorylation of
mTOR and S6K in a time- and dosage-dependent manner.
However, the lower doses of the oxidants, such as 0.5 M PAO
and 30 mM diamide, significantly promoted the phosphoryla-
Figure 2.H2O2 inhibits phosphorylationofmTOR substrates.A, dosage effect of H2O2 onphosphorylation ofmTOR substrates.C, time-dependent effect of
100 M H2O2 on phosphorylation of mTOR substrates. E, H2O2 inhibits insulin-induced mTOR activation. Western blot analyses with the indicated antibodies
were performed. B,D, and F, relative signal intensities of the phosphorylated/total proteins shown inA (B),C (D), and E (F).n 3–6 (B), 3–8 (D), and 3–4 (F).p
0.05 versus basal levels (B and D). NR, Western blot analyses with non-reducing SDS-PAGE; Ox, oxidized form; Red, reduced form. Western blot results were
verified by two to three (A), two (C), and three to four (E) additional independent experiments.
Figure 3. H2O2 inhibits mTOR kinase activity. Cardiomyocytes were
treated with 100 M H2O2 for 0.5 and 1 h. Immunoprecipitation (IP) of mTOR
was performed with anti-mTOR antibody. An in vitro kinase assay was per-
formedwith immunoprecipitatedmTORand recombinant 4EBP1.n3.p
0.05.
Trx1 as a co-factor ofmTOR
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tion of S6K at 30 min (Fig. 4, A–D). Phosphorylation of mTOR
tended to increase under these conditions. Phosphorylation of
mTOR and S6K were significantly inhibited by H2O2 in a time-
and dosage-dependent manner, but the phosphorylation
tended to increase with a lower dosage of H2O2 at 10 min (Fig.
2, A–C). Thus, the oxidants, including H2O2, PAO, and
diamide, induce similar effects on phosphorylation of mTOR
and S6K. On the other hand, PAO and diamide up-regulated
both phosphorylated and total 4EBP1 (Fig. 4, A and C), which
differs from H2O2. The ratio of phosphorylated/total 4EBP1
was not significantly inhibited at 30 min by any of the dosages
we tested, but it was significantly inhibited by 5 M PAO and
100 M diamide in a time-dependent manner. The decreased
ratio of phosphorylated/total 4EBP1 may indicate mTOR inhi-
bition. Taken together, these results suggest that oxidants,
including H2O2, PAO, and diamide, are able to inhibit mTOR
signaling but that there are several oxidant-specific effects, such
as mTOR disulfide bond formation and 4EBP1 regulation, in
cardiomyocytes.
Trx1 potentiatesmTORC1 activity under oxidative stress
conditions
To test whether Trx1 has a regulatory role in mTOR oxida-
tion and activity, the effects of Trx1 overexpression and knock-
down upon phosphorylation of mTORC1 substrates were
examined. Although the oxidation status ofmTOR as indicated
by the band shift was not affected by overexpression or down-
regulation of Trx1 alone, H2O2-induced mTOR oxidation was
inhibited byTrx1 overexpression and enhanced byTrx1 knock-
down, suggesting that Trx1 reduces disulfide bonds in mTOR
(Fig. 5A). As shown in Fig. 5, A and B, Trx1 overexpression
alone did not significantly affect phosphorylation ofmTOR and
its substrates, whereas Trx1 knockdown alone inhibited phos-
phorylation. Trx1 overexpression normalized the decrease in
phosphorylation of mTOR and its substrates in the presence of
H2O2, whereas the decrease in phosphorylation was enhanced
by Trx1 knockdown. These results suggest that Trx1 potenti-
ates mTORC1 activity in cardiomyocytes in the presence of
H2O2.
The role of Trx1-mediatedmTOR regulation
To test whether Trx1 potentiatesmTOR activity in the heart,
phosphorylation of mTOR substrates was examined in Trx1
heterozygous knock-out (Trx1/) mice under ischemic con-
ditions. The band shift of mTOR because of oxidation was
detected in Trx1/ but not in wild-type mice under ischemic
conditions, suggesting that endogenous Trx1 reduces disulfide
bonds in mTOR in the heart in vivo (Fig. 6A). Phosphorylation
Figure4.Phenylarsineoxide (PAO)anddiamide inhibitphosphorylationofmTORandS6K.A, dosageeffect of PAO (left panel) and time-dependent effect
of 5M PAO (right panel) on phosphorylation of mTOR substrates. C, dosage effect of diamide (left panel) and time-dependent effect of 100M diamide (right
panel) on phosphorylation ofmTOR substrates. B andD, relative signal intensities of the phosphorylated/total proteins shown in A (B) and C (D). n 3–8. p
0.05 versus basal levels (B and D). NR, Western blot analyses with non-reducing SDS-PAGE. Open and closed arrows indicate oxidized and reduced mTOR,
respectively. Western blot results were verified by two to three additional independent experiments.
Trx1 as a co-factor ofmTOR
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ofmTOR and its substrates was inhibited by ischemia, an effect
that was further enhanced in Trx1/ mice (Fig. 6, B and C).
These results suggest that endogenous Trx1 plays an important
role in preserving mTORC1 activity in the heart during ische-
mia in vivo. Simulated ischemia–reperfusion (IR) induces oxi-
dative stress in cultured cardiomyocytes (17). As shown in Fig.
6D, IR-inducedmTORoxidationwas enhanced byTrx1 knock-
down. In addition, phosphorylation of mTOR substrates under
IR conditions was inhibited by Trx1 knockdown (Fig. 6, D and
E). As expected, IR-induced cell death was enhanced by Trx1
knockdown (Fig. 6F). Taken together, these results suggest that
endogenous Trx1 preserves mTOR activity under oxidative
stress conditions, whichmay, in turn, promote cell survival dur-
ing IR.
Trx1 potentiatesmTOR-mediatedmitochondrial function
To test whether Trx1-induced cytoprotection is mediated by
mTOR, cardiomyocyte viability was examined. H2O2-induced
decreases in cardiomyocyte viability were normalized by Trx1
overexpression, but this protective effect was abolished in the
presence of rapamycin, an mTORC1 inhibitor (Fig. 7A). These
results suggest that Trx1-induced cytoprotection is mediated
bymTOR. Expression of nucleus-encodedmitochondrial genes
is positively regulated bymTOR at both the transcriptional and
translational levels (18, 19). To test whether Trx1 potentiates
mitochondrial function in an mTOR-dependent manner, ATP
content and mitochondrial ATP production were examined.
Both ATP content and mitochondrial ATP production were
significantly inhibited by H2O2, whereas Trx1 conferred partial
normalization, which was abolished in the presence of rapa-
mycin (Fig. 7, B andC). Mitochondrial damage promotes mito-
chondrial ROS production (20). To investigate whether Trx1
prevents mitochondrial ROS production in an mTOR-depen-
dent manner, we used HyPer-mito, a fluorescence-based H2O2
indicator that localizes to mitochondria. Induction of mito-
chondrial H2O2 production by exogenous H2O2 treatment was
inhibited by Trx1, whereas the inhibitory effect of Trx1 was
abolished in the presence of rapamycin (Fig. 7D). This result
suggests that Trx1 prevents mitochondrial H2O2 production in
an mTOR-dependent manner. Consistently, Trx1 knockdown
promoted H2O2-induced cell death and exacerbated H2O2-in-
duceddecreases inATPcontent (Fig. 7,E andF).H2O2-induced
down-regulation of mitochondrial genes such as Atp5a,
Uqcrc2,Mtco1, Sdhb, and Ndufb8 was normalized by Trx1, an
effect that was abolished in the presence of rapamycin (Fig. 7G).
Trx1 knockdown promoted H2O2-induced down-regulation of
mitochondrial genes (Fig. 7H). Taken together, these results
suggest that Trx1-induced cytoprotection against oxidative
stress in cardiomyocytes is partlymediated through normaliza-
tion of mTOR activation.
The Cys-1483 residue is responsible formTOR oxidation and
inhibition
To identify a cysteine residue responsible for mTOR oxida-
tion and inhibition, we first investigated which part of mTOR
forms a disulfide bond using Myc-tagged mTOR-truncated
mutants (Fig. 8A). The molecular weight shift caused by inter-
molecular disulfide bond formation was observed most
prominently in mTOR(1271–2008), suggesting that the region
flanking the FRAP-ATM-TTRAP (FAT) domain contains a
redox-sensitive cysteine (Fig. 8B). It has been reported that oxi-
dation-resistant mutations at Cys-1483, including C1483F,
C1483P, and C1483Y, are highly recurrent in cancer patients
and enhance mTOR activity (21). We hypothesized that Cys-
1483 is a residue responsible for mTOR redox regulation. Cys-
1483 is evolutionally conserved in multiple cellular organisms
(Fig. 8C). To test whether Cys-1483 mediates disulfide bond
formation in mTOR, Myc-mTOR-C1483F was expressed in
HEK293 cells. H2O2-induced oxidation of mTOR was attenu-
ated in Myc-mTOR-C1483F, suggesting that Cys-1483 is
involved in disulfide bond formation (Fig. 8D). To test whether
Cys-1483 is reduced by Trx1, the interaction between mTOR-
C1483F andTrx1C35Swas examined. The interaction between
mTOR and Trx1C35S was attenuated in the presence of
mTOR-C1483F compared with intact mTOR under both basal
and H2O2-treated conditions, suggesting that Trx1C35S forms
an intermolecular disulfide bond with mTOR at Cys-1483 (Fig.
8E). To test the extent to which Cys-1483 mediates H2O2-in-
Figure 5. Trx1 normalizes H2O2-inducedmTORoxidation and inhibition.
A, left panel, overexpression of Trx1 normalizes H2O2-induced mTOR oxida-
tion and inhibition. After 2 days of Trx1 adenovirus vector transduction, car-
diomyocyteswere incubatedwith100MH2O2 for 30min.Right panel, knock-
down of Trx1 enhances H2O2-inducedmTOR oxidation and inhibition. After 3
days of shTrx1 transduction, cardiomyocytes were incubated with 100 M
H2O2 for 30min. Each lane corresponds to an independent sample (n3).NR,
non-reducing SDS-PAGE; Ox, oxidized form; Red, reduced form. B, relative
signal intensities of the phosphorylated/total proteins shown in A. n 4–11.
p 0.05.
Trx1 as a co-factor ofmTOR
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duced mTOR inhibition, phosphorylation of mTOR substrates
was examined. As shown in Fig. 8F, mTOR-C1483F conferred
resistance against H2O2-induced dephosphorylation of S6K
and 4EBP1, suggesting that Cys-1483 mediates H2O2-in-
duced mTOR inhibition (Fig. 8F). Similarly, mTOR-C1483F
conferred resistance against H2O2-induced cell death (Fig.
8G) and down-regulation of mitochondrial proteins (Fig.
8H). Taken together, these results suggest that mTOR Cys-
1483 is subjected to oxidation and can be reduced by Trx1.
Discussion
In this study, we show that mTOR undergoes intermolecular
disulfide formation in response to oxidative stress and that
intermolecular disulfide bond formation at Cys-1483 is respon-
sible for H2O2-induced mTOR inhibition. Trx1 serves as an
electron donor to reduce the disulfide in mTOR, thereby posi-
tively regulating phosphorylation of mTOR substrates (Fig. 9).
The mechanism by which Cys-1483 oxidation inhibits
mTOR is currently unknown. It is likely that mTOR forms
intermolecular disulfide bonds eitherwith anothermTORmol-
ecule or with a distinct molecule (Fig. 1G). The identity of the
molecule with which mTOR forms an intermolecular disulfide
bond remains to be elucidated. Because oxidation of mTOR
negatively affects mTOR phosphorylation at Ser-2448 and Ser-
2481, it is likely that the disulfide bond formation negatively
regulates phosphorylation of mTOR by upstream kinases or by
mTOR itself (autophosphorylation) through changes in the
structure of mTOR because of either the oxidation itself or
protein–protein interaction. The Cys-1483 mutation abolishes
binding to Deptor, an inhibitory protein for mTOR (21). It will
be interesting to test whether oxidation of Cys-1483 enhances
the binding of Deptor to mTOR.
Missense mutations at Cys-1483 such as the C1483F muta-
tion are highly recurrent in cancer patients (21). Resistance
against oxidative stress may be an underlying mechanism by
which themutations at Cys-1483 contribute to cancer develop-
ment. It has been proposed that Trx1 confers stress resistance,
thereby increasing the malignancy of cancer (5). Trx1-medi-
ated maintenance of mTOR function may confer stress resis-
tance in cancer cells.
We showed that H2O2 inhibits mTORC1 activity, as evi-
denced by reduced phosphorylation of endogenous substrates
and by impairedmTOR kinase activity, determined by immune
complex kinase assays. On the other hand, H2O2 alone did not
Figure 6. Trx1 has a regulatory role in mTOR signaling under ischemia and ischemia-reperfusion conditions. A, ischemia-induced mTOR oxidation in
Trx1/mice. B, haploinsufficiency of Trx1 promotes ischemia-induced mTOR inhibition. Heart lysates were prepared after 3 h of ischemia. Each lane corre-
sponds to an individual mouse. C, relative signal intensities of theWestern blot results shown in B. n 4–6.D, knockdown of Trx1 enhances IR-inducedmTOR
oxidation. Cardiomyocyteswere transducedwith shTrx1 for 5 days. Themyocyteswere incubatedwith 95%nitrogen 5%CO2 for 4 h and then incubated under
normal cell culture conditions (5%CO2) for 30min. C and E, relative signal intensities of the phosphorylated/total proteins shown in B (C) andD (E). n 4–6 (C)
and 4–8 (E). F, knockdown of Trx1 enhances IR-induced cell death. After 16 h of reoxygenation, cardiomyocyte viability was examined by trypan blue dye
exclusion. n 4–6.NR, non-reducing SDS-PAGE;Ox, oxidized form; Red, reduced form.Western blot resultswere verified by two (A and B), and two to three (D)
additional independent experiments. p 0.05.
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significantly inhibit phosphorylation of Akt, an mTORC2
substrate. However, H2O2 did inhibit insulin-induced Akt
phosphorylation. How H2O2 affects the overall function of
mTORC2 remains to be clarified.
Although mTOR activity was consistently suppressed after
30 min of H2O2 treatment at multiple concentrations, phos-
phorylation ofmTOR targets tended to be increased transiently
around 10 min in response to low concentrations of H2O2
despite oxidation of mTOR (Fig. 2, A–D). We speculate that
another H2O2-sensitive mechanismmay independently stimu-
late mTOR. There are conflicting reports showing that oxida-
tive stress either activates or inhibits mTOR. H2O2 inhibits
mTOR in primary cultured neurons and A549, PC12, and
RAW264.7 cells (13, 22, 23). On the other hand, several oxi-
dants, such as PAO and diamide, activate mTOR in HEK293
cells andmouse embryonic fibroblasts (11, 12). In this study, we
showed thatmTOR signaling is inhibited bymultiple dosages of
PAO and diamide and at multiple time points but that mTOR
Figure 7. The Trx1-induced cytoprotective effect is mediated bymTOR. A, Trx1 protects against H2O2-induced cell death throughmTOR activation. After
2 days of Trx1 adenovirus vector transduction, cardiomyocytes were treated with 30 M H2O2 and 10 nM rapamycin for 6 h. Cardiomyocyte viability was
examined by trypan blue dye exclusion. n 4–10. B–D, Trx1 protects against H2O2-inducedmitochondrial damage throughmTOR activation. After 2 days of
Trx1 adenovirus vector transduction, cardiomyocytes were treatedwith 100MH2O2 and 10 nM rapamycin for 6 h. ATP content (B), ATP production in isolated
mitochondria (C), and mitochondrial H2O2 production (D) were inhibited by H2O2 but were normalized by Trx1 overexpression. The Trx1-mediated normal-
ization was abolished by rapamycin. n 4–10 (B and C) and 4 (D). E and F, Trx1 protects against H2O2-induced cell death and reduction of ATP content. After
4–5 days of shTrx1 adenovirus vector transduction, cardiomyocytes were treatedwith 30M (E) or 100M (F) H2O2 for 6 h. Cardiomyocyte viability (E) and ATP
content (F) were examined. n 4 (E) and 3–5 (F).G, left panel, H2O2 inhibitedmitochondrial protein expression, whichwas normalized by Trx1 overexpression.
The Trx1-mediated normalization ofmitochondrial protein expressionwas abolished by rapamycin. Right panel, relative signal intensities of theWestern blot.
n 3–4.H, left panel, H2O2 inhibitedmitochondrial protein expression, an effect that was enhanced by Trx1 knockdown. Right panel, relative signal intensities
of the Western blot. n 3–4. p 0.05.
Trx1 as a co-factor ofmTOR
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signaling tended to be activated transiently at low concentra-
tions (Fig. 4). Although previous studies have shown that both
PAO and diamide activate mTOR, the experiments were con-
ductedwith only one dosage at one timepoint (11, 12). Thus,we
speculate that mTOR signaling may be activated transiently by
a low level of oxidative stress, whereas it may be inhibited by
higher levels of oxidative stress, with the extent of oxidative
stress and time course of activation or inhibition of mTOR
varying in each cell type.
Our results show that Trx1 interacts with mTOR through
an intermolecular disulfide bond. Because this interaction is
hardly observed between endogenous Trx1 and mTOR (Fig.
Figure 8. The Cys-1483 residue is responsible formTOR redox regulation. A, schematic ofmTOR-truncatedmutants. B, the indicatedmTORmutants were
expressed in HEK293 cells. After 3 mM H2O2 treatment for 30 min, Western blot analyses were performed after SDS-PAGE under non-reducing (without 2ME)
and reducing (with 2ME) conditions. C, Cys-1483 is evolutionarily conserved among multi-cellular organisms. D, Cys-1483 is responsible for H2O2-induced
mTOR oxidation. Myc-mTOR andMyc-mTOR-C1483Fwere expressed in HEK293 cells. After 1 and 3mMH2O2 treatment for 30min,Western blot analyses were
performed after SDS-PAGE under non-reducing conditions. LE, long exposure; SE, short exposure; Ox, oxidized form; Red, reduced form. E, Cys-1483 is a Trx1
reduction site. The indicated Myc-mTOR mutants and FLAG-Trx1C35S-HA were expressed in HEK293 cells. After 3 mM H2O2 treatment for 30 min, co-immu-
noprecipitation assays were performed with anti-FLAG antibody. Western blot analyses were performed with anti-Myc and anti-HA antibodies. F, left panel,
Cys-1483 is responsible for H2O2-inducedmTOR inhibition. Myc-mTOR-C1483F and HA-GST-S6K were expressed in HEK293 cells. After H2O2 treatment (1 and
3mM, 30min),Western blot analyseswere performedwith the indicated antibodies. Right panel, relative signal intensities of phosphorylated/total protein.n
4–7.G, the C1483Fmutation confers resistance against H2O2-induced cell death. HEK293 cells expressingMyc-mTOR orMyc-mTOR-C1483Fwere treatedwith
1 mM H2O2 for 6 h. Cell viability was examined. n  4. H, left panel, the C1483F mutation confers resistance against H2O2-induced down-regulation of
mitochondrial proteins. Right panel, relative signal intensities of the Western blot. n 3–6. Western blot results were verified by two (B), three (D and E), and
two to three (F) additional independent experiments. p 0.05.
Trx1 as a co-factor ofmTOR
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1D) and becomes obvious only when a Trx1-trappingmutant is
used (Fig. 1, B andC), it is likely that Trx1 interacts withmTOR
transiently to reduce mTOR with disulfide bonds at Cys-1483.
Because down-regulation of endogenous Trx1 exacerbates oxi-
dation ofmTORand suppresses phosphorylation ofmTOR tar-
gets, we propose that Trx1 acts as an endogenous co-factor of
mTOR, thereby protecting mTOR from oxidation and inac-
tivation during oxidative stress. Although this investigation
strongly suggests that Trx1 regulates the oxidation status of
mTOR through direct protein–protein interaction, it is for-
mally possible that Trx1 also indirectly prevents mTOR oxi-
dation by scavenging H2O2 through Trx1-dependent peroxi-
dases (6).
Thioredoxin-binding protein-2 (TBP-2)/thioredoxin-inter-
acting protein (TXNIP) was originally identified as a Trx1
inhibitor (24). Consistent with our results, there are several
reports showing that TBP-2 inhibits mTOR (25, 26). However,
it has also been reported that TBP-2 is required for diabetes-
induced mTOR activation (27). We have reported previously
that TBP-2 serves as a scaffolding protein and is required for
Trx1-mediated thiol exchange reactions for specific Trx1 sub-
strates, including class II histone deacetylases (28). Thus,
TBP-2may serve as a scaffolding protein for mTOR to undergo
thiol exchange reactions in a context-dependent manner.
Whether TBP-2 promotes or inhibits Trx1-mediated thiol
exchange reactions of mTOR remains to be elucidated.
Cardiac-specific overexpression of Trx1 ameliorates pres-
sure overload–induced cardiac hypertrophy (29) and high-fat
diet–induced exacerbation of ischemic injury (4). Cardiac-spe-
cific overexpression of Trx1 also attenuates mitochondrial dys-
function in septic mice (30). Trx1 acts as an antioxidant to
reduce H2O2 through activation of peroxiredoxin (6). In addi-
tion, Trx1 reduces the oxidized form of histone deacetylase 4
(HDAC4) (28) and AMPK (4), thereby protecting the heart
against cardiac hypertrophy and ischemic injury. We here pro-
pose that mTOR is another target of Trx1 that mediates the
protective effect of Trx1 in cardiomyocytes. Although Trx1
negatively regulates cardiac hypertrophy (29, 31), mTOR can
positively regulate cardiac hypertrophy by promoting protein
translation (9). Thus, how Trx1-induced positive regulation of
mTOR affects the overall level of cardiac hypertrophy may be
determined by the balance between the direct effect upon car-
diac hypertrophy and the improvement of cardiac perfor-
mance. It is possible that Trx1-induced decreases in cell death
and improvement of mitochondrial function secondarily
inhibit pathological hypertrophy.
We show here that Trx1 positively affects mitochondrial
function through mTOR in cardiomyocytes. Oxidative stress
down-regulates expression of mitochondrial genes, including
Atp5a,Uqcrc2,Mtco1, Sdhb, andNdufb8, inhibits ATPproduc-
tion, and induces cell death in cardiomyocytes. These detri-
mental effects of oxidative stress are accompanied by suppres-
sion of mTOR, whereas they are alleviated in the presence of
Trx1 through a rapamycin-sensitive mechanism, suggesting
that the cardioprotective effect of the Trx1–mTOR pathway
may be in part mediated through protection of mitochondria
against oxidative stress. Consistently, Trx1 knockdown pro-
moted H2O2-induced down-regulation of mitochondrial genes
(Fig. 7H). It is possible that Trx1 knockdown and H2O2 (100
M) have additive effects, and, thus, that their effects are medi-
ated through independentmechanisms. However, because oxi-
dation of mTOR by 100 M H2O2 is further enhanced by Trx1
knockdown (Fig. 5A), Trx1 knockdown and H2O2 (100 M)
presumably act through the same targets. To test whether Trx1
knockdown and H2O2 act through independent mechanisms,
we would have to test whether Trx1 knockdown can still
enhance H2O2-induced down-regulation of mitochondrial
genes at the maximum dose of H2O2. Unfortunately, higher
dosages of H2O2 induced prominent cell death in the presence
of Trx1 knockdown so that we were not able to address this
issue in a reliable manner. Thus, the possibility that Trx1
knockdown and H2O2 independently down-regulate mito-
chondrial genes cannot be excluded.
mTOR up-regulates mitochondrial genes through PGC-1–
dependent transcriptional regulation and 4EBP1-dependent
translational regulation (18, 19). We have reported that cardi-
ac-specific overexpression of Trx1 up-regulates nucleus-en-
coded mitochondrial genes possessing a nuclear respiration
factor-1 (NRF1)–binding element in their promoter regions
(32). PGC-1 co-activates NRF1 (33). Thus, the Trx1–mTOR
pathwaymaypositively regulatemitochondrial gene expression
through PGC-1–NRF1 signaling. Moreover, the H2O2-in-
duced decrease in 4EBP1 phosphorylation is attenuated by
Trx1 in an mTOR-dependent manner (Fig. 7G). Taken
together, these findings indicate that theTrx1–mTORpathway
maintains mitochondrial function in the presence of oxidative
stress through multiple mechanisms.
Whether mTOR is protective or detrimental in the failing
heart remains controversial (10). AlthoughmTOR protects the
heart by enhancing mitochondrial function and cell survival,
it may negatively affect the heart through inhibition of
autophagy. Increased protein translation is an energy-consum-
ing process and can negatively affect survival of cardiomyocytes
in the presence ofmyocardial ischemia (34). Thus, a novel strat-
egy promoting only the protective aspects of mTOR function,
such as the enhancement of mitochondrial function, while pre-
ventingmTOR-mediated inhibition of autophagywould poten-
tially be beneficial for treatment of patients with cardiac stress.
We have shown previously that Trx1 activates AMPK, an
inducer of autophagy (4). Thus, enhancing the function of Trx1
may be an attractive strategy that enhances the salutary actions
of mTOR while minimizing its detrimental aspects through
stimulation of AMPK.
In summary, this study shows that mTOR is an important
downstream target of Trx1. Trx1 acts as an endogenous co-fac-
tor of mTOR to inhibit disulfide bond formation and maintain
Figure9. Schematicmodel.ThemTORkinase is inhibitedbyoxidative stress,
possibly through intermolecular disulfide formation. Trx1 protects against
oxidative stress, partly through mTOR.
Trx1 as a co-factor ofmTOR
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the activity of mTOR. mTOR plays a critical role in mediating
the protective effect of Trx1 in the heart, possibly by preserving
mitochondrial function during oxidative stress.
Experimental procedures
Transgenicmice
Cardiac-specific Trx1C35S transgenic mice on the Friend
virus B (FVB) background have been described previously (4).
Trx1/ mice were described previously (35). Trx1/ mice
were backcrossed to C57BL/6 mice more than 12 times. Ische-
mia was achieved by ligation of the anterior descending branch
of the left coronary artery, with silicon tubing (1 mm outer
diameter) placed on top of the artery, 2 mm below the border
between the left atrium and left ventricle. All procedures
involving animals were performed in accordance with proto-
cols approved by Rutgers Biomedical and Health Sciences.
Immunoblot analysis
Heart homogenates or cell lysates were prepared using a lysis
buffer (50 mM Tris-HCl (pH 7.6), 1% Triton X-100, 10 mM
EDTA, 150 mM NaCl, 50 mM NaF, and protease inhibitor mix-
ture (Sigma)). Total protein lysates (10–30 g) were incubated
with SDS sample buffer (final concentration: 100 mM Tris (pH
6.8), 2% SDS, 5% glycerol, 2.5% 2-mercaptoethanol, and 0.05%
bromphenol blue) at 95 °C for 5–20 min. For mTOR redox sta-
tus analyses, the lysateswere preparedwith lysis buffer contain-
ing 20 mM N-ethylmaleimide and SDS sample buffer without
2-mercaptoethanol. For immunoprecipitation, the lysates were
incubated with FLAG-agarose or anti-mTOR antibody with
protein A-agarose. Immunocomplexes were washed with lysis
buffer three times and eluted with 2 SDS sample buffer.
Antibodies used for this study were Trx1 (Cell Signaling Tech-
nology, 2429), mTOR (Cell Signaling Technology, 2797), phos-
pho-mTOR(Ser-2448) (Cell Signaling Technology, 2796),
phospho-mTOR(Ser-2481) (Cell Signaling Technology, 2774),
p70 S6 kinase (Cell Signaling Technology, 9202), phospho-p70
S6 kinase (Cell Signaling Technology, 9205), 4EBP1 (Cell Sig-
naling Technology, 9644), phospho-4EBP1 (Cell Signaling
Technology, 2855), Akt (Cell Signaling Technology, 9272),
phospho-Akt (Cell Signaling Technology, 9271), tubulin
(Sigma, T6199), Myc (Cell Signaling Technology, 2272), FLAG
(Cell Signaling Technology, 2368), and MitoProfile contain-
ing antibodies against Atp4a, Uqcrc2, Mtco1, Sdhb, and
Ndfub8 (Mitoscience, MS604). The signal intensity ofWestern
blot signals was quantified using the ImageJ program. The sig-
nal intensity of non-phosphorylated proteins was normalized
by a loading control, tubulin. The signal intensity of phosphor-
ylated proteins was normalized by that of total protein. Differ-
ences in signal intensities derived from different Western blot
membranes were reported as relative changes and combined to
generate line or bar graphs.
In vitro kinase assay
Cardiomyocytes were treated with 100 M H2O2 for 0.5 and
1h.mTORwas immunoprecipitatedwith anti-mTORantibody
and protein A/G-agarose. The immunocomplex was washed
with 1 ml of lysis buffer twice and with 1 ml of kinase buffer (50
mM HEPES (pH 7.4), 15 mM MgCl2, and 200 M sodium vana-
date) twice. In vitro kinase reactions were performed with
mTOR in the kinase buffer, 2 g of recombinant 4EBP1
(Novus) and 100MATPat room temperature for 30min in the
kinase buffer. The kinase reaction was terminated with 2 SDS
sample buffer. Phosphorylation levels of 4EBP1 were examined
by Western blot analyses with anti-phospho-4EBP1 antibody.
Primary cultures of neonatal rat ventricularmyocytes
Primary cultures of cardiomyocytes were prepared form
1-day-old Crl:(WI) BR-Wistar rats (Harlan). A cardiomyocyte-
rich fraction was obtained by centrifugation through a discon-
tinuous Percoll gradient. Cells were cultured in complete
medium containing Dulbecco’s modified Eagle’s medium/F-12
supplemented with 5% horse serum, 4 g/ml transferrin, 0.7
ng/ml sodium selenite, 2 g/liter bovine serum albumin (fraction
V), 3 mM pyruvate, 15 mM HEPES (pH 7.1), 100 M ascorbate,
100 mg/liter ampicillin, 5 mg/liter linoleic acid, and 100 M
5-bromo-2-deoxyuridine. Culture dishes were coated with
0.3% gelatin.
Simulated ischemia reperfusion
Cardiomyocytes were placed in a hypoxia chamber with 95%
N2 and 5% CO2 for 4 h and then transferred to a standard CO2
incubator.
ATP content
Cardiomyocytes were lysed with somatic cell ATP releasing
reagent (Sigma, FLSAR). The ATP content in the lysates was
measured with an ATP bioluminescent assay kit (Sigma,
FLAA).
ATP production in isolatedmitochondria
Mitochondria were freshly isolated from cardiomyocytes
(6-cm culture dish) using amitochondrion isolation kit (Sigma,
MITOISO1). The isolated mitochondria were suspended in 50
l of storage buffer (10 mM HEPES (pH 7.4), 250 mM sucrose,
and 2mMK2HPO4). ATP productionwasmeasured by lumino-
metric assay using an ATP bioluminescent assay kit (Sigma,
FLAA). TheATP assaymixture was dilutedwith dilution buffer
(1000-fold dilution). The dilutedATP assaymixture (25l) was
combined with 25l of substrate buffer (5mMHEPES (pH 7.9),
210 mM mannitol, 70 mM sucrose, 10 mM pyruvate, 10 mM
malate, and 4 mM K2HPO4), and then 5 l of mitochondrial
solution was added. After 5 min of incubation at room temper-
ature, the reaction was started by addition of 1 l of 12.5 mM
ADP. The luminescence was measured by luminometer for
10 s.
Mitochondrial H2O2 production
Adenovirus vector expressing HyPer-mito was transduced
into cardiomyocytes. After 2–3 days of transduction, fluores-
cence (excitation, 500 nm; emission, 520 nm) was detected by
fluorescence microcopy.
Adenovirus vectors
Adenoviruses harboring Trx1, shTrx1, FLAG-Trx1C35S-
HA, and HyPer-mito were generated using the AdMax system
(Microbix) as described previously (4, 36).
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Plasmid vectors
The mammalian expression vectors for mTOR, including
pRK5-Myc-mTOR, pRK5-Myc-mTOR(1–1482), pRK5-Myc-
mTOR(1271–2008), pRK5-Myc-mTOR(1750–2549), and pRK5-
HA-GST-p85S6K, were gifts from Dr. David Sabatini (Add-
gene; 1861, 21745, 21746, 21747, and 8466). The mTOR cDNA
from pRK5-Myc-mTOR was inserted into pDC316 with an
N-terminal FLAG tag to generate pDC316-FLAG-mTOR.
pRK5-Myc-mTOR-C1483F was generated by site-directed
mutagenesis.
Statistical methods and error bars
Statistical comparisons weremade using Student’s t test. p
0.05 was defined as statistically significant and is indicated by a
star. p 0.05 is indicated by NS (not significant). All error bars
represent S.E.
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